Table 4.
The efficacy of peripheral zone prostate-specific antigen density to diagnose prostate cancer in patients with negative multiparameter magnetic resonance imaging and transrectal ultrasound results (prostate imaging reporting and data system ≤3)
| Group | PSA 4.0–10.0 ng ml−1 | PSA 10.1–20.0 ng ml−1 | PSA >20.0 ng ml−1 | Total |
|---|---|---|---|---|
| TRUS/MRI (−), n | 135 | 78 | 22 | 235 |
| Pathology (+), n (%) | 22 (16.3) | 18 (23.1) | 11 (50.0) | 51 (21.7) |
| PZ-PSAD cutoff value (ng ml−2) | 0.105 | 0.436 | 1.803 | |
| PZ-PSAD (+), n (%) | 45 (33.3) | 19 (24.4) | 11 (50.0) | 75 (31.9) |
| PZ-PSAD (+) pathology (+), n | 17 | 14 | 10 | 41 |
PSA: prostate-specific antigen; PZ-PSAD: peripheral zone prostate-specific antigen density; PCa: prostate cancer; TRUS: transrectal ultrasound; mpMRI: multiparameter magnetic resonance imaging; PIRADS: Prostate Imaging Reporting and Data System; TRUS/MRI (-): without suspicious nodules or a PIRADS score ≤ 3; pathology (+): prostate cancer; PZ-PSAD (+): PZ-PSAD > cut-off value